Memo Therapeutics Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 24

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $27.7M

  • Investors
  • 17

Memo Therapeutics General Information

Description

Developer of antibody discovery and immune repertoire analysis platform designed to transform the lives of patients with virus infections and cancer. The company's platform creates a recombinant in vitro copy of an individual's B cell/antibody repertoire that leads to entirely new possibilities in immune repertoire analysis and antibody discovery, enabling physicians to progress molecular cloning, biobanking, and expression-screening of all the antibodies in an organism.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Corporate Office
  • Wagistrasse 27
  • 8952 Schlieren
  • Switzerland
+41 079 000 00 00

Memo Therapeutics Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Memo Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series C) 02-Nov-2023 $27.7M 000.00 000.00 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series B) 16-Feb-2022 000.00 000.00 000.00 Completed Clinical Trials - Phase 2
4. Grant 13-Dec-2021 000.00 00.000 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series A2) 17-Dec-2018 00.000 00.000 000.00 Completed Pre-Clinical Trials
2. Grant 10-Jul-2017 $2.35M Completed Startup
1. Early Stage VC (Series A) 01-Apr-2015 $2.35M $2.35M 00.000 Completed Startup
To view Memo Therapeutics’s complete valuation and funding history, request access »

Memo Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 000,000 00.000000 000.00 000.00 00 000.00 00.000
Series B 00,000 00.000000 000.00 000.00 00 000.00 0.000
Series B 000,000 00.000000 000.00 000.00 00 000.00 00.000
Series A2 00,000 00.000000 000.00 000.00 00 000.00 0.000
Series A2 31,795 $1.106853 $70.04 $70.04 1x $70.04 2.96%
Series A1 84,958 $1.106853 $29.96 $29.96 1x $29.96 7.9%
To view Memo Therapeutics’s complete cap table history, request access »

Memo Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of antibody discovery and immune repertoire analysis platform designed to transform the lives of patients with
Drug Discovery
Schlieren, Switzerland
24 As of 2023
000.00
000.00 0000-00-00
00000000000 000.00

00000

am, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo cons
0000 000000000
Cambridge, United Kingdom
000 As of 0000
00000
00.000 0000-00-00
000000&0 00000

000000

in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
0000000000000
Oklahoma City, OK
000 As of 0000
0000
00000 0000-00-00
000000&0 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Memo Therapeutics Competitors (33)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kymab Formerly VC-backed Cambridge, United Kingdom 000 00000 000000&0 00000
Cytovance Biologics Formerly PE-Backed Oklahoma City, OK 000 0000 000000&0 0000
Kineta Formerly VC-backed Seattle, WA 00 00000 000000000 00000
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA 0000 00.000 0000 00.000
Hookipa Pharma Formerly VC-backed New York, NY 000 00000 000000000 00000
You’re viewing 5 of 33 competitors. Get the full list »

Memo Therapeutics Executive Team (8)

Name Title Board Seat Contact Info
Lars Spenger Chief Financial Officer & Head of Finance
Christoph Esslinger Ph.D Co-Founder, Chief Scientific Officer & Board Member
Erik Berg CEO
Dragan Gabulovski Strategic Advisor
Jurgen Beck MD Chief Medical Officer
You’re viewing 5 of 8 executive team members. Get the full list »

Memo Therapeutics Board Members (13)

Name Representing Role Since
Andreas Wüpper Ph.D Fresenius Medical Care Ventures Board Member 000 0000
Christian Schneider Ph.D Vesalius Biocapital Partners Board Member 000 0000
Christoph Esslinger Ph.D Memo Therapeutics Co-Founder, Chief Scientific Officer & Board Member 000 0000
Elias Papatheodorou Self Chairman 000 0000
Philippe Dro Adjuvant Capital Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Memo Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Memo Therapeutics Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Kinled Family Office 000 0000 000000 0
Pureos Bioventures Venture Capital Minority 000 0000 000000 0
Adjuvant Capital Impact Investing Minority 000 0000 000000 0
Bernina BioInvest Venture Capital Minority 000 0000 000000 0
Fresenius Medical Care Ventures Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 17 investors. Get the full list »

Memo Therapeutics FAQs

  • When was Memo Therapeutics founded?

    Memo Therapeutics was founded in 2012.

  • Who is the founder of Memo Therapeutics?

    Christoph Esslinger Ph.D is the founder of Memo Therapeutics.

  • Where is Memo Therapeutics headquartered?

    Memo Therapeutics is headquartered in Schlieren, Switzerland.

  • What is the size of Memo Therapeutics?

    Memo Therapeutics has 24 total employees.

  • What industry is Memo Therapeutics in?

    Memo Therapeutics’s primary industry is Drug Discovery.

  • Is Memo Therapeutics a private or public company?

    Memo Therapeutics is a Private company.

  • What is the current valuation of Memo Therapeutics?

    The current valuation of Memo Therapeutics is 000.00.

  • What is Memo Therapeutics’s current revenue?

    The current revenue for Memo Therapeutics is 000000.

  • How much funding has Memo Therapeutics raised over time?

    Memo Therapeutics has raised $74.8M.

  • Who are Memo Therapeutics’s investors?

    Kinled, Pureos Bioventures, Adjuvant Capital, Bernina BioInvest, and Fresenius Medical Care Ventures are 5 of 17 investors who have invested in Memo Therapeutics.

  • Who are Memo Therapeutics’s competitors?

    Kymab, Cytovance Biologics, Kineta, Alnylam Pharmaceuticals, and Hookipa Pharma are some of the 33 competitors of Memo Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »